Nongenital Warts Questions & Answers

1. Luria L, Cardoza-Favarato G. Human Papillomavirus. StatPearls [Internet]. 2020 Jan. [QxMD MEDLINE Link]. [Full Text].

2. Cohen PR, Hebert AA, Adler-Storthz K. Focal epithelial hyperplasia: Heck disease. Pediatr Dermatol. 1993 Sep. 10(3):245-51. [QxMD MEDLINE Link].

3. Mallory SB, Baugh LS, Parker RK. Warts in blacks versus whites. Pediatr Dermatol. 1991 Mar. 8(1):91. [QxMD MEDLINE Link].

4. Silverberg NB. Human papillomavirus infections in children. Curr Opin Pediatr. 2004 Aug. 16(4):402-9. [QxMD MEDLINE Link].

5. Guadara J, Sergi A, Labruna V, Welch M, Gazivoda PL. Transformation of plantar verruca into squamous cell carcinoma. J Foot Surg. 1992 Nov-Dec. 31(6):611-4. [QxMD MEDLINE Link].

6. Kolker AR, Wolfort FG, Upton J, Tahan SR, Hein KD, Zewert TE. Plantar verrucous carcinoma following transmetatarsal amputation and renal transplantation. Ann Plast Surg. 1998 May. 40(5):515-9. [QxMD MEDLINE Link].

7. Noel JC, Detremmerie O, Peny MO, et al. Transformation of common warts into squamous cell carcinoma on sun-exposed areas in an immunosuppressed patient. Dermatology. 1994. 189(3):308-11. [QxMD MEDLINE Link].

8. Holland TT, Weber CB, James WD. Tender periungual nodules. Myrmecia (deep palmoplantar warts). Arch Dermatol. 1992 Jan. 128(1):105-6, 108-9. [QxMD MEDLINE Link].

9. Bellew SG, Quartarolo N, Janniger CK. Childhood warts: an update. Cutis. 2004 Jun. 73(6):379-84. [QxMD MEDLINE Link].

10. Goldfarb MT, Gupta AK, Gupta MA, Sawchuk WS. Office therapy for human papillomavirus infection in nongenital sites. Dermatol Clin. 1991 Apr. 9(2):287-96. [QxMD MEDLINE Link].

11. [Guideline] Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British Association of Dermatologists' guidelines for the management of cutaneous warts 2014. Br J Dermatol. 2014 Oct. 171(4):696-712. [QxMD MEDLINE Link].

12. Kwok CS, Gibbs S, Bennett C, Holland R, Abbott R. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2012 Sep 12. 9:CD001781. [QxMD MEDLINE Link].

13. Cockayne S, Hewitt C, Hicks K, et al. Cryotherapy versus salicylic acid for the treatment of plantar warts (verrucae): a randomised controlled trial. BMJ. 2011 Jun 7. 342:d3271. [QxMD MEDLINE Link]. [Full Text].

14. Mizuki D, Kaneko T, Hanada K. Successful treatment of topical photodynamic therapy using 5-aminolevulinic acid for plane warts. Br J Dermatol. 2003 Nov. 149(5):1087-8. [QxMD MEDLINE Link].

15. Perrett CM, Harwood C, Brown V. Topical 5% imiquimod treatment for refractory cutaneous warts. J Am Acad Dermatol. 2004. 50(3):P41.

16. Padilla España L, Del Boz J, Fernández-Morano T, Escudero-Santos I, Arenas-Villafranca J, de Troya M. Recalcitrant warts and topical cidofovir: predictive factors of good response. J Eur Acad Dermatol Venereol. 2015 Apr 10. [QxMD MEDLINE Link].

17. Padilla España L, Del Boz J, Fernández Morano T, Arenas-Villafranca J, de Troya M. Successful treatment of periungual warts with topical cidofovir. Dermatol Ther. 2014 Nov-Dec. 27 (6):337-42. [QxMD MEDLINE Link].

18. Cleary A, Watson R, McMahon CJ. Successful treatment of refractory cutaneous warts using topical 3% cidofovir in a child after heart transplant. J Heart Lung Transplant. 2014 Sep. 33 (9):971-2. [QxMD MEDLINE Link].

19. Padilla España L, Del Boz J, Fernández Morano T, Arenas Villafranca J, de Troya Martín M. Topical cidofovir for plantar warts. Dermatol Ther. 2014 Mar-Apr. 27 (2):89-93. [QxMD MEDLINE Link].

20. Gupta M, Bayliss SJ, Berk DR. Topical cidofovir for refractory verrucae in children. Pediatr Dermatol. 2013 Jan-Feb. 30 (1):131-4. [QxMD MEDLINE Link].

21. Gladsjo JA, Alio Saenz AB, Bergman J, Krikorian G, Cunninghan BB. 5% 5-fluorouracil cream for treatment of verruca vulgaris in children. Pediat Dermatol. 2009. 26:279-285.

22. Horn TD, Johnson SM, Helm RM, Roberson PK. Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Arch Dermatol. 2005 May. 141(5):589-94. [QxMD MEDLINE Link].

23. James MP, Collier PM, Aherne W, et al. Histologic, pharmacologic, and immunocytochemical effects of injection of bleomycin into viral warts. J Am Acad Dermatol. 1993 Jun. 28(6):933-7. [QxMD MEDLINE Link].

24. Munn SE, Higgins E, Marshall M, Clement M. A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. Br J Dermatol. 1996 Dec. 135(6):969-71. [QxMD MEDLINE Link].

25. Ohtsuki A, Hasegawa T, Hirasawa Y, Tsuchihashi H, Ikeda S. Photodynamic therapy using light-emitting diodes for the treatment of viral warts. J Dermatol. 2009. 36:525-528.

26. Yilmaz E, Alpsoy E, Basaran E. Cimetidine therapy for warts: a placebo-controlled, double-blind study. J Am Acad Dermatol. 1996 Jun. 34(6):1005-7. [QxMD MEDLINE Link].

27. Kottke MD, Parker SR. Intravenous cidofovir-induced resolution of disfiguring cutaneous human papillomavirus infection. J Am Acad Dermatol. 2006 Sep. 55(3):533-6. [QxMD MEDLINE Link].

28. McAleer MA, Bourke J. Intravenous cidofovir for resistant cutaneous warts in a patient with psoriasis treated with monoclonal antibodies. Clin Exp Dermatol. 2011 Aug. 36 (6):638-40. [QxMD MEDLINE Link].

29. Cusack C, Fitzgerald D, Clayton TM, Irvine AD. Successful treatment of florid cutaneous warts with intravenous cidofovir in an 11-year-old girl. Pediatr Dermatol. 2008 May-Jun. 25 (3):387-9. [QxMD MEDLINE Link].

30. Potthoff A, Wieland U, Kreuter A. Failure of intravenous cidofovir for generalized verrucosis in a patient with severe combined immunodeficiency. Arch Dermatol. 2012 May. 148 (5):659-60. [QxMD MEDLINE Link].

31. Focht DR 3rd, Spicer C, Fairchok MP. The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart). Arch Pediatr Adolesc Med. 2002 Oct. 156(10):971-4. [QxMD MEDLINE Link].

32. Wenner R, Askari SK, Cham PM, Kedrowski DA, Liu A, Warshaw EM. Duct tape for the treatment of common warts in adults: a double-blind randomized controlled trial. Arch Dermatol. 2007 Mar. 143(3):309-13. [QxMD MEDLINE Link].

33. Ewin DM. Hypnotherapy for warts (verruca vulgaris): 41 consecutive cases with 33 cures. Am J Clin Hypn. 1992 Jul. 35(1):1-10. [QxMD MEDLINE Link].

34. Zedan H, Hofney ERM, Ismail SA. Propolis as an alternative treatment for cutaneous warts. Internat J Dermatol. 2009. 48:1246-1249.

35. Silverberg NB. Garlic cloves for verruca vulgaris. Pediatr Dermatol. 2002 Mar-Apr. 19(2):183. [QxMD MEDLINE Link].

36. Millar BC, Moore JE. Successful topical treatment of hand warts in a paediatric patient with tea tree oil (Melaleuca alternifolia). Complement Ther Clin Pract. 2008 Nov. 14(4):225-7. [QxMD MEDLINE Link].

37. Mahran AM, Twisy HO, Elghazally SA, Badran AY. Evaluation of different concentrations of hydrogen peroxide solution (3% and 6%) as a potential new therapeutic option of nongenital warts: A randomized controlled triple-blinded clinical trial. J Cosmet Dermatol. 2020 Feb. 19 (2):416-422. [QxMD MEDLINE Link].

38. Bourke JF, Berth-Jones J, Hutchinson PE. Cryotherapy of common viral warts at intervals of 1, 2 and 3 weeks. Br J Dermatol. 1995 Mar. 132(3):433-6. [QxMD MEDLINE Link].

39. Berth-Jones J, Hutchinson PE. Modern treatment of warts: cure rates at 3 and 6 months. Br J Dermatol. 1992 Sep. 127(3):262-5. [QxMD MEDLINE Link].

40. Gloster HM Jr, Roenigk RK. Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J Am Acad Dermatol. 1995 Mar. 32(3):436-41. [QxMD MEDLINE Link].

41. Boroujeni NH, Handjani F, Saki N. CO₂ laser treatment for plantar warts in children: A case series. Dermatol Ther. 2020 May. 33 (3):e13414. [QxMD MEDLINE Link].

42. Sloan K, Haberman H, Lynde CW. Carbon dioxide laser-treatment of resistant verrucae vulgaris: retrospective analysis. J Cutan Med Surg. 1998 Jan. 2(3):142-5. [QxMD MEDLINE Link].

43. Hughes PS, Hughes AP. Absence of human papillomavirus DNA in the plume of erbium:YAG laser-treated warts. J Am Acad Dermatol. 1998 Mar. 38(3):426-8. [QxMD MEDLINE Link].

44. Rivera A, Tyring SK. Therapy of cutaneous human Papillomavirus infections. Dermatol Ther. 2004. 17(6):441-8. [QxMD MEDLINE Link].

Philip D Shenefelt, MD, MS Professor, Department of Dermatology and Cutaneous Surgery, University of South Florida College of Medicine; Past Chief, Section of Dermatology, James A Haley Veteran Affairs Medical Center

Philip D Shenefelt, MD, MS is a member of the following medical societies: American Academy of Dermatology, Florida Medical Association, Noah Worcester Dermatological Society, Society for Clinical and Experimental Hypnosis, American Contact Dermatitis Society, American Association for Physician Leadership, American Medical Association, American Society of Clinical Hypnosis

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Lester F Libow, MD Dermatopathologist, South Texas Dermatopathology Laboratory

Lester F Libow, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, Texas Medical Association

Disclosure: Nothing to disclose.

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD<br/>Served as a speaker for various universities, dermatology societies, and dermatology departments.

Joshua A Zeichner, MD Assistant Professor, Director of Cosmetic and Clinical Research, Mount Sinai School of Medicine; Chief of Dermatology, Institute for Family Health at North General

Joshua A Zeichner, MD is a member of the following medical societies: American Academy of Dermatology, National Psoriasis Foundation

Disclosure: Received consulting fee from Valeant for consulting; Received grant/research funds from Medicis for other; Received consulting fee from Galderma for consulting; Received consulting fee from Promius for consulting; Received consulting fee from Pharmaderm for consulting; Received consulting fee from Onset for consulting.

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Margaret H. Rinker, MD, to the development and writing of this article.

• Print this section
• Print the entire contents of
• Print the entire contents of article